Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-04-21
Schrödinger, Inc.
Schrödinger sells computational chemistry and discovery workflow software to pharma, biotech, industrial, and academic customers while also advancing collaborative and proprietary drug programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Cleaner software story with option-rich upside
The upside case is not a moonshot drug jackpot. It is a cleaner hosted discovery-software business with deeper workflow ownership, modest module expansion, and therapeutics upside monetized through partners instead of balance-sheet-heavy internal development.

Analysis

Thesis
Schrödinger can create solid 5-year equity upside if LiveDesign becomes a deeper governed workflow layer for AI-native drug discovery, new software modules widen wallet share, and therapeutics upside is monetized mainly through partners and royalties rather than a renewed self-funded biotech burn model.
Last Economy Alignment
Cheaper compute and better models make Schrödinger’s simulation-heavy workflows more valuable, but it does not control the compute stack and still faces internalization risk from large pharma.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.6x (from 5 most recent analyses)
Reasoning
I am underwriting a rerating from a messy software-plus-biotech story to a cleaner vertical-science software business with capped but real royalty optionality. The upside comes from durable contract growth, hosted revenue visibility, broader workflow ownership, and selective asset monetization; the ceiling stays below pure AI-drug-discovery leaders because clinical proof and pricing power are still incomplete.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof transfer: Schrödinger must show that its software can become a true discovery control layer, not just a useful modeling tool, while keeping internal therapeutics from becoming a capital sink. If hosted deployments hide weak demand, large customers internalize more workflow, or SGR-3515 and partnering fail to validate the platform-derived asset engine, the stock can remain a low-multiple niche science-software name.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.55
They control a sticky discovery workspace where drug teams coordinate models, data, and decisions, and cheaper AI makes that workspace more useful. The risk is that large pharma builds more in-house tooling or lets agents bypass parts of the interface, which would weaken pricing power.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.50
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case